Kadmon Holdings
Kadmon Holdings is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases. Founded in 2010 and headquartered in New York, Kadmon's lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of rho-associated coiled-coil kinase 2, which is in Phase II clinical trials for chronic graft-versus-host disease and fibrotic diseases; KD045, an oral inhibitor of ROCK for fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for cancer treatment. The company also develops Tesevatinib for autosomal dominant polycystic kidney disease, ribavirin for hepatitis, and CLOVIQUE for Wilson’s disease. Kadmon has strategic collaborations with Nano Terra and Dyax Corp.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
Three Rivers Pharmaceuticals
Acquisition in 2010
Three Rivers Pharmaceuticals, LLC develops, manufactures, and markets generic pharmaceutical drug products in the United States and internationally. It offers prescription drugs in the therapeutic categories of antiviral and antifungal agents. The company’s products include AMPHOTEC for the treatment of invasive aspergillosis, a systemic fungal infection; and INFERGEN, RIBASPHERE tablets, RIBASPHERE capsules, and RibaPak tablets for the treatment of hepatitis C. It also markets Topotecan Hydrochloride for injection. Three Rivers Pharmaceuticals, LLC was founded in 2000 and is based in Warrendale, Pennsylvania. As of October 25, 2010, Three Rivers Pharmaceuticals, LLC operates as a subsidiary of Kadmon Pharmaceuticals LLC.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.